EMPIRI provides valuable support for drug discovery companies through its E-Slice assay, a novel, 3D tumor tissue culture platform that maintains the complexity and integrity of individual cancer patient’s tumor outside of the body, providing the best model to empirically test which drugs are most effective for that patient. E-slice is unique in that it maintains the native tumor microenvironment – including immune cells – unique to each cancer to faithfully recapitulate patient therapeutic responses. It can be used to enhance both preclinical drug discovery and development efforts and clinical diagnosis.

EMPIRI is also a trusted 10X Genomics Certified Service Provider, delivering end-to-end or a la carte single-cell sequencing services. Our services cover tissue dissociation, basic bioinformatics analysis, and everything in between, enabling us to provide high-quality single-cell RNA sequencing from samples such as 18-gauge biopsy cores obtained from clinical trial samples. Our expertise in single-cell sequencing has proven to be instrumental in maximizing the information gained during clinical trials and other important scientific research.